Analyst Reports
Date | Report | Author |
---|---|---|
February 13 |
Start of a promising year |
![]() |
February 13 |
Lovande start på nytt år |
![]() |
January 6 |
Q4 2024 financial results (EN) |
![]() |
Date | Report | Author |
---|---|---|
December 9 |
Start för fas 1 inom kort (SE) |
![]() |
December 9 |
Austrian milestone (EN) |
![]() |
November 14 |
Q3 2024 financial results (EN) |
![]() |
November 1 |
Reverse Split (EN) |
![]() |
October 21 |
Early stage biotech company with a phase 3 validated platform |
![]() |
October 15 |
SIIPL Term Sheet (EN) |
![]() |
August 22 |
At the gates of Phase I (EN) |
![]() |
August 22 |
Vid porten till fas 1 (SE) |
![]() |
August 15 |
2024 Second Quarter Results (EN) |
![]() |
July 11 |
2024 Rights Issue results (EN) |
![]() |
May 23 |
Improving cash position (EN) |
![]() |
May 23 |
Förbättrat kassa inför fas1 (SE) |
![]() |
May 16 |
024 First Quarter Results (EN) |
![]() |
May 3 |
2024 Rights Issue (EN) |
![]() |
April 23 |
AdaptVac Dividend (EN) |
![]() |
April 16 |
Completion of pre-clinical safety (EN) |
![]() |
February 22 |
ABNCoV2 milestone payment (EN) |
![]() |
February 15 |
Breast cancer on stage (EN) |
![]() |
February 15 |
Bröstcancer i fokus (SE) |
![]() |
February 8 | 2023 YE Report (Newsflash) (EN) | ![]() |
Date | Report | Author |
---|---|---|
December 4 |
Pipeline addition - Nipah |
![]() |
December 4 |
Spotlight: Cancer vaccine ES2B-C001 |
![]() |
November 27 |
New strategy evolving (EN) |
![]() |
November 27 |
Ny strategi tar form (SE) |
![]() |
August 17 |
Evaluating BC strategic options (Newsflash) (EN) |
![]() |
June 27 |
ABNCoV2 phase II meets primary endpoint (Newsflash) (EN) |
![]() |
June 16 |
ABNCoV2 strong durability data (Newsflash) (EN) |
![]() |
May 16 |
2023 Q1 Report (Newsflash) (EN) |
![]() |
April 18 |
Initial gross proceeds of SEK 54.5m (EN) |
![]() |
March 15 |
Ever-changing landscape (EN) |
![]() |
March 15 |
Ett föränderligt landskap (SE) |
![]() |
March 6 |
2023 Right Issue Announcement (EN) |
![]() |
March 3 |
Mucosal Vaccine (EN) |
![]() |
February 9 |
2022 YE Report Newsflash (EN) |
![]() |
Date | Report | Author |
---|---|---|
December 6 |
Evaxion CMV vaccine collaboration Newsflash (EN) |
![]() |
November 18 |
Promising long-term data (EN) |
![]() |
November 18 |
Lovande långtidsdata (SE) |
![]() |
November 17 |
9M 2022 Report Newsflash (EN) |
![]() |
October 24 |
ES2B-C001 positive preclinical data published (EN) |
![]() |
October 18 |
ABNCoV2 reports positive phase II durability data (EN) |
![]() |
September 22 |
COVID vaccine phase III trial ongoing (EN) |
![]() |
April 8 |
Cash position to be further increased (EN) |
![]() |
March 8 |
A moving target (EN) |
![]() |
March 8 |
Ett rörligt mål (SE) |
![]() |
March 1 |
Further progress with COVID-19 vaccine (EN) |
![]() |
January 10 |
Exciting topline preclinical results for ES2B-C001 (EN) |
![]() |
Date | Report | Author |
---|---|---|
December 9 |
Solid data open for final phase (EN) |
![]() |
December 9 |
Resultat öppnar vägen för slutfas (SE) |
![]() |
December 7 |
Great ABNCoV2 Phase II top line results (EN) |
![]() |
November 19 |
Phase 2 data pending (EN) |
![]() |
November 19 |
Fas 2-resultat inom kort (SE) |
![]() |
November 17 |
COVID-19 vaccine Phase II readout on the horizon (EN) |
![]() |
August 23 |
Funding still pending (EN) |
![]() |
August 23 |
I väntan på finansiering (SE) |
![]() |
August 20 |
Initiation of Phase II trial just around the corner (EN) |
![]() |
August 9 |
Great COUGH-1 headline results (EN) |
![]() |
June 24 |
Rights to COVID-19 Challenge (Initiation) (EN) |
![]() |
April 22 |
First human data reassuring (EN) |
![]() |
April 22 |
Första data på människa (SE) |
![]() |
January 27 |
Getting Close To Patients (EN) |
![]() |
January 27 |
Test På Människa Inom Kort (SE) |
![]() |
Date | Report | Author |
---|---|---|
September 3 |
Broadening the Portfolio (EN) |
![]() |
September 3 |
Minskad risk med breddad portfölj (SE) |
![]() |
June 8 |
I den stora kapplöpningen (SE) |
![]() |
Date | Report | Author |
---|---|---|
November 21 |
Potential at Reduced Risk (EN) |
![]() |
November 21 |
Potential till Reducerad Risk (SE) |
![]() |
English reports
Analysguiden
22 August 2024 | Analysguiden - At the gates of Phase I
23 May 2024 | Analysguiden - Improving cash position
15 February 2024 | Analysguiden - Breast cancer on stage
27 Nov 2023 | Analysguiden - New strategy evolving
15 Mar 2023 | Analysguiden - Ever-changing landscape
18 Nov 2022 | Analysguiden - Promising long-term data
13 Jun 2022 | Analyseguiden - Preparing for the final
8 Mar 2022 | Analysguiden - A moving target
9 Dec 2021 | Analysguiden - Solid data open for final phase
19 Nov 2021 | Analysguiden - Phase 2 data pending
23 Aug 2021 | Analysguiden - Funding still pending
22 Apr 2021 | Analysguiden - First human data reassuring
27 Jan 2021 | Analysguiden - Getting Close To Patients
3 Sep 2020 | Analysguiden - Broadening the Portfolio
21 Nov 2019 | Analysguiden - Potential at Reduced Risk
Pareto Securities
17 October 2024 Pareto | SIIPL Term Sheet
15 August 2024 Pareto | 2024 Second Quarter Results
11 July 2024 Pareto | 2024 Rights Issue results
16 May 2024 Pareto | 2024 First Quarter Results
3 May 2024 Pareto | 2024 Rights Issue
23 April 2024 Pareto | AdaptVac Dividend
16 April 2024 Pareto | Completion of pre-clinical safety
22 February 2024 Pareto | ABNCoV2 milestone payment
8 February 2024 Pareto | 2023 YE Report (Newsflash)
4 December 2023 Pareto | Pipeline addition - Nipah
4 December 2023 Pareto | Spotlight: Cancer vaccine ES2B-C001
17 August 2023 | Pareto - Evaluating BC strategic options (Newsflash)
27 June 2023 Pareto | ABNCoV2 phase II meets primary endpoint (Newsflash)
16 June 2023 Pareto | ABNCoV2 strong durability data (Newsflash)
16 May 2023 Pareto | 2023 Q1 Report (Newsflash)
18 April 2023 Pareto | Initial gross proceeds of SEK 54.5m
6 March 2023 Pareto | 2023 Right Issue Announcement
3 March 2023 Pareto | Mucosal Vaccine
9 February 2023 Pareto | 2022 YE Report Newsflash
6 December 2022 Pareto | Evaxion CMV vaccine collaboration Newsflash
17 November 2022 Pareto | 9M 2022 Report Newsflash
24 Oct 2022 Pareto | ES2B-C001 positive preclinical data published
18 Oct 2022 Pareto | ABNCoV2 reports positive phase II durability data
22 Sep 2022 Pareto | COVID vaccine phase III trial ongoing
8 Apr 2022 Pareto | Cash position to be further increased
1 Mar 2022 Pareto | Further progress with COVID-19 vaccine
10 Jan 2022 Pareto | Exciting topline preclinical results for ES2B-C001
7 Dec 2021 | Pareto - Great ABNCoV2 Phase II top line results
17 Nov 2021 | Pareto - COVID-19 vaccine Phase II readout on the horizon
20 Aug 2021 | Pareto - Initiation of Phase II trial just around the corner
9 Aug 2021 | Pareto - Great COUGH-1 headline results
24 Jun 2021 | Pareto - Rights to COVID-19 Challenge (Initiation)
Swedish reports
Analysguiden
22 August 2024 | Analysguiden - Vid porten till fas 1
23 May 2024 | Analysguiden - Förbättrat kassa inför fas1
15 February 2024 | Analysguiden - Bröstcancer i fokus
27 Nov 2023 | Analysguiden - Ny strategi tar form
15 Mar 2023 | Analysguiden - Ett föränderligt landskap
18 Nov 2022 | Analysguiden - Lovande långtidsdata
13 Jun 2022 | Analysguiden - Bavarian nära fas 3-start
8 Mar 2022 | Analysguiden - Ett rörligt mål
9 Dec 2021 | Analysguiden - Resultat öppnar vägen för slutfas
19 Nov 2021 | Analysguiden - Fas 2-resultat inom kort
23 Aug 2021 | Analysguiden - I väntan på finansiering
22 Apr 2021 | Analysguiden - Första data på människa
27 Jan 2021 | Analysguiden -Test På Människa Inom Kort
3 Sep 2020 | Analysguiden - Minskad risk med breddad portfölj